Part of our series, AI in healthcare. Written by William Riley, VP, Commercial Analytics.
Artificial intelligence (AI) is reshaping the healthcare landscape, offering new opportunities to address some of the most complex challenges in specialty pharmacy. For health systems that operate specialty pharmacies, AI provides practical capabilities to enhance patient care, improve operational efficiency, and expand financial sustainability. By leveraging these advancements, hospital-owned specialty pharmacies are well-positioned to drive innovation in value-based care, optimize the benefits of the 340B program, and achieve meaningful improvements in both outcomes and access.
This piece looks at how AI applies across specialty pharmacy operations, patient care, value-based care, and 340B, what it means for the manufacturers who place limited-distribution drugs, and where human judgment still has to lead. It is a core part of AI in pharmacy practice.
AI-drive specialty pharmacy operations
Hospital-owned specialty pharmacies handle high-cost medications, intricate treatment regimens, and complex payer landscapes. AI tools are proving invaluable in streamlining these processes. Predictive analytics optimize inventory management, keeping the right medications available without overstocking or waste. Similarly, machine learning algorithms are expediting prior authorization workflows, reducing administrative burdens, and accelerating time-to-therapy for patients.
AI also enhances revenue cycle management by identifying overlooked reimbursement opportunities and improving billing accuracy. For health systems, this translates to increased financial sustainability while continuing to meet patients’ needs effectively. As the demands on specialty pharmacies grow, operational efficiencies driven by AI are becoming essential to maintain quality and scalability.
How does AI support specialty pharmacy patient outcomes
The integration of AI into clinical workflows allows specialty pharmacies to enhance patient care in ways previously unattainable. Using data from electronic health records (EHRs), AI can identify patients at risk of nonadherence, adverse events, or suboptimal treatment outcomes. These insights enable pharmacists to deliver targeted interventions, such as adherence monitoring, tailored education, or adjustments to therapy based on predictive models.
Natural language processing (NLP) tools and AI-driven chatbots support patient engagement by providing timely, accessible communication. These technologies help patients manage their medications, answer questions, and adhere to prescribed therapies, all of which contribute to better clinical outcomes. For health systems, this level of engagement not only improves individual care but also strengthens the broader institutional mission of delivering high-quality, patient-centered services.
AI in value-based specialty care
AI is a powerful enabler of value-based care, a model increasingly embraced by health systems. By analyzing large datasets, AI can quantify outcomes, measure quality metrics, and assess the total cost of care for specialty therapies. These insights support health systems in negotiating value-based contracts with manufacturers and payers, aligning reimbursement with clinical outcomes rather than volume alone. AI also allows hospital-owned specialty pharmacies to identify high-risk patients and stratify them for proactive, cost-effective interventions. This approach reduces avoidable hospitalizations and emergency visits while improving overall patient outcomes. As a result, AI not only enhances care but also strengthens the financial case for value-based models.
How AI strengthens the 340B and specialty overlap
For health systems, the 340B Drug Pricing Program represents a critical opportunity to enhance both access and financial performance. AI tools can analyze prescribing patterns, support compliance, and streamline audit processes, maximizing the benefits of the program.
AI also enables hospitals to identify underserved patient populations and expand their 340B footprint. With the savings realized through optimized 340B operations, health systems can reinvest in community programs, improve access to specialty care, and fund critical health initiatives. For a deeper look, read our companion post on AI 340B optimization.
What manufacturers should expect from an AI-enabled specialty partner
Manufacturers deciding where to place a limited-distribution or rare-disease therapy are evaluating a partner’s ability to move patients to treatment quickly and keep them there. An AI-enabled specialty partner should be able to speak to a specific set of measures: time to therapy, time to fill, adherence, patient outcomes, and disease outcomes, backed by data rather than assertion. Just as important is the care continuum around the patient, including caseworker support and family support for the households managing a complex diagnosis. The right partner uses AI to compress the administrative path to treatment and to document outcomes, so a manufacturer can see how its therapy performs in the real world and trust that patients are supported end to end.
Specialty pharmacy by the numbers
More than 50% of US pharmaceutical spending now goes to specialty drugs, even though they affect less than 5% of the population. (CarelonRx, citing IQVIA)
0.89 average PDC medication adherence for rheumatoid arthritis patients at an integrated health-system specialty pharmacy, versus a 0.44–0.70 range reported at conventional pharmacies. (AJMC)
~75% of the roughly 7,000 drugs now in development are specialty medicines. (CarelonRx)
The future of AI in specialty pharmacy
Looking ahead, the role of AI in hospital-owned specialty pharmacies will only expand. Advances in precision medicine, digital therapeutics, and generative AI are poised to transform how rare and complex diseases are treated. As these technologies integrate further with EHR systems and care coordination platforms, hospital-owned specialty pharmacies will become even more central to institutional efforts to improve outcomes and reduce costs.
For health systems, the strategic adoption of AI is a long-term investment, not just an operational upgrade. By embracing AI-driven innovation, specialty pharmacies can deliver superior care, align with value-based care goals, and unlock the full potential of programs like 340B. In doing so, they will not only improve patient lives but also strengthen the long-term sustainability of healthcare delivery.
Final thoughts
Artificial intelligence represents a pivotal opportunity for health systems to reimagine the role of specialty pharmacy, leveraging technology to advance both institutional goals and community health. The organizations that gain the most will be the ones that move thoughtfully, pairing capable technology with accountable people, and that can show manufacturers and patients alike a measurably faster, safer path to therapy.
Further reading
See how VytlAIQ can help your health system move specialty patients to therapy faster. Learn more about VytlAIQ or contact us to talk with our team.
Frequently asked questions
How does AI work in specialty pharmacy?
AI works in specialty pharmacy by automating and guiding the steps between a prescription and a filled, adhered-to therapy. It reads electronic health record and referral data to speed intake, predicts prior-authorization needs, flags patients at risk of nonadherence, and recommends the next best action for a pharmacy liaison. Natural language processing (NLP) pulls detail from clinical notes, and predictive analytics manage inventory for high-cost drugs. The goal is faster time to therapy, higher adherence, and clearer outcome data for health systems and manufacturers, with clinicians making the consequential decisions.
How does AI reduce time to therapy?
AI reduces time to therapy by removing the delays that stall specialty starts. It automates intake, captures referrals that would otherwise be missed, predicts and prepares prior authorizations, and surfaces benefit and financial-assistance options early. Rather than working a queue in order, staff get a prioritized, rule-based list of next best actions, so the patients closest to a barrier get attention first. For limited-distribution and rare-disease drugs, where every day matters, compressing this intake-to-fill arc can move a patient to treatment materially faster.Â
How does AI support specialty pharmacy patient outcomes?
AI supports outcomes by keeping patients on therapy and catching problems early. Integrated health-system specialty pharmacies already report strong adherence: one study of rheumatoid arthritis patients found an average proportion of days covered of 0.89, well above the 0.44 to 0.70 range reported at conventional pharmacies. AI extends that advantage by predicting nonadherence, prompting timely outreach, and orchestrating caseworker and family support around the patient. For manufacturers, that means better disease outcomes and cleaner real-world evidence on the therapies they entrust to a specialty partner.
How does AI shorten time to fill?
Time to fill is the stretch between a clean, approved prescription and the medication in the patient’s hands. AI shortens it by automating benefit verification, predicting inventory needs for high-cost drugs so the right therapy is on hand, and coordinating shipping and patient scheduling. Workflow automation removes manual handoffs that add days, and exception flags route only the hard cases to a person. The result is fewer stockouts, fewer rework loops, and a faster, more predictable path from approval to fill.
How does AI work for limited-distribution drugs?
Limited-distribution drugs (LDDs) are specialty medicines a manufacturer releases through a small, chosen set of pharmacies. AI helps an LDD partner prove it can move patients to therapy quickly and safely by capturing referrals, managing tight inventory, predicting adherence, and documenting the outcome and disease data manufacturers want to see. Because LDD populations are small and often rare-disease, models must be used carefully and paired with human clinical judgment. Done well, AI-enabled specialty pharmacy is part of what makes a health system a credible home for a manufacturer’s limited-distribution therapy.
How does AI support pediatric rare-disease pharmacy?
Pediatric rare-disease care is high-touch, low-volume, and unforgiving of delay, which is where AI and a strong care continuum matter most. AI speeds intake and referral capture, predicts adherence risk, and helps coordinate the caseworker and family support these patients depend on. Because rare-disease data is sparse, models trained on majority populations can be biased, so human clinicians stay in the loop on every consequential decision. VytlOne’s specialization in pediatric rare disease, cystic fibrosis, and pulmonary care pairs that clinical depth with AI to move fragile patients to therapy faster.
Â